» Articles » PMID: 33326819

Psychological Comorbidity in Gastrointestinal Diseases: Update on the Brain-gut-microbiome Axis

Overview
Specialty Psychiatry
Date 2020 Dec 16
PMID 33326819
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The high comorbidity of psychological disorders in both functional and organic gastrointestinal diseases suggests the intimate and complex link between the brain and the gut. Termed the brain-gut axis, this bidirectional communication between the central nervous system and enteric nervous system relies on immune, endocrine, neural, and metabolic pathways. There is increasing evidence that the gut microbiome is a key part of this system, and dysregulation of the brain-gut-microbiome axis (BGMA) has been implicated in disorders of brain-gut interaction, including irritable bowel syndrome, and in neuropsychiatric disorders, including depression, Alzheimer's disease, and autism spectrum disorder. Further, alterations in the gut microbiome have been implicated in the pathogenesis of organic gastrointestinal diseases, including inflammatory bowel disease. The BGMA is an attractive therapeutic target, as using prebiotics, probiotics, or postbiotics to modify the gut microbiome or mimic gut microbial signals could provide novel treatment options to address these debilitating diseases. However, despite significant advancements in our understanding of the BGMA, clinical data is lacking. In this article, we will review current understanding of the comorbidity of gastrointestinal diseases and psychological disorders. We will also review the current evidence supporting the key role of the BGMA in this pathology. Finally, we will discuss the clinical implications of the BGMA in the evaluation and management of psychological and gastrointestinal disorders.

Citing Articles

Rising of natural therapies: Potential and challenges of traditional Chinese medicine in the management of gastrointestinal diseases.

Tian X, Zhan J, Qiao C, Ge J, Li D World J Gastroenterol. 2025; 31(9):103145.

PMID: 40061595 PMC: 11886042. DOI: 10.3748/wjg.v31.i9.103145.


Role of the gut microbiome in psychological symptoms associated with inflammatory bowel diseases.

Atanasova K, Knodler L, Reindl W, Ebert M, Thomann A Semin Immunopathol. 2025; 47(1):12.

PMID: 39870972 PMC: 11772462. DOI: 10.1007/s00281-025-01036-x.


Changes in RNA Splicing: A New Paradigm of Transcriptional Responses to Probiotic Action in the Mammalian Brain.

Yue X, Zhu L, Zhang Z Microorganisms. 2025; 13(1).

PMID: 39858933 PMC: 11767420. DOI: 10.3390/microorganisms13010165.


Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis.

Hassib L, Kanashiro A, Pedrazzi J, Vercesi B, Higa S, Arruda I Brain Behav Immun Health. 2025; 43():100923.

PMID: 39839986 PMC: 11745983. DOI: 10.1016/j.bbih.2024.100923.


Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and gut microbiota composition: what do we know?.

Tagi V, Tosi M, Greco I, Stucchi E, Verduci E, Zuccotti G Front Nutr. 2025; 11():1477893.

PMID: 39834450 PMC: 11743372. DOI: 10.3389/fnut.2024.1477893.


References
1.
Davis C . The Gut Microbiome and Its Role in Obesity. Nutr Today. 2016; 51(4):167-174. PMC: 5082693. DOI: 10.1097/NT.0000000000000167. View

2.
Camara R, Gander M, Begre S, von Kanel R . Post-traumatic stress in Crohn's disease and its association with disease activity. Frontline Gastroenterol. 2013; 2(1):2-9. PMC: 3854716. DOI: 10.1136/fg.2010.002733. View

3.
Khoury B, Lecomte T, Fortin G, Masse M, Therien P, Bouchard V . Mindfulness-based therapy: a comprehensive meta-analysis. Clin Psychol Rev. 2013; 33(6):763-71. DOI: 10.1016/j.cpr.2013.05.005. View

4.
Sexton K, Walker J, Graff L, Bernstein M, Beatie B, Miller N . Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(3):473-483. DOI: 10.1097/MIB.0000000000001040. View

5.
Raison C, Rutherford R, Woolwine B, Shuo C, Schettler P, Drake D . A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2012; 70(1):31-41. PMC: 4015348. DOI: 10.1001/2013.jamapsychiatry.4. View